FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562505734> ?p ?o ?g. }

• W2562505734 abstract "Purpose Cancer represents a significant burden on the economy. The NCI estimated that this cost will exceed $158 billion in 2020. As cancer-related costs increase, it is pertinent to explore alternative treatment strategies. The advent of cancer genome sequencing has had a profound effect on the perception of the current treatment standards. Recent findings suggest a transition to a new treatment paradigm in which targeted therapies are chosen based upon unique genetic alterations regardless of cancer type. The purpose of this cost analysis is to assess the impact of genomic-directed treatment on the direct cost of therapy. Methodology A systematic search was conducted in a database that consisted of 64 patients that had undergone genetic sequencing. The study included patients that had a molecular genomics profile completed and excluded patients without any treatable genetic mutations. The data analyzed included patient9s previous treatment and its costs. Standard doses were assumed in the cost analysis if no dose was provided in the chart. The genomic directed treatment was determined by the genomic oncology team based upon the findings from the molecular genomic profile report. The standard next line therapy was determined from progress notes in the patient chart before they were referred to genomic sequencing, or chosen using the NCCN guidelines. All costs were calculated using wholesale acquisition costs from REDBOOK Online. Results Ten patients were analyzed. All patients received adjuvant systemic chemotherapy that followed current treatment standards reflected by the NCCN guidelines. Before being referred to the genomic sequencing service, the number of previous regimens ranged from 1 to 10 lines of therapy over durations that varied from 18 - 76 months. The total cost of treatment before sequencing ranged from $12,722.59 - $396,197.19 with the treatment cost/ month ranging from $978.66 - $12,381.16. Potential standard next -line therapy ranged from $4403.09 - $12,370.06/month and the genomic-directed therapy ranged from $7,231.46 - $22,469.87/month. As expected, most of the genomic-directed therapy regimens were more expensive than the potential standard next-line therapy. In 1 patient, the genomic-directed therapy was less expensive than the potential standard next-line therapy. Conclusion Genomic-directed therapy is more expensive than current treatment standards due to the use of newer and more expensive biologic agents. However, current standard therapies focus on the location of the disease and do not target the specific driving feature of the malignancy. The current approach often results in the use of multiple agents in multiple lines of therapy, consequently driving up the cost of therapy. Genomic-directed therapy may result in better outcomes that translate to less treatment being needed and a decrease in the total cost of treatment. Further studies are needed to assess the benefit of genomic-directed therapy. Citation Format: Seth Tutera, Marissa Olson, Casey Williams, Brian Leyland-Jones, Mark Huber, Heidi McKean, Addison Tolentino. Cost analysis of genomic-directed therapy in patients with metastatic lung and colorectal cancers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5494. doi:10.1158/1538-7445.AM2015-5494" @default.
• W2562505734 created "2017-01-06" @default.
• W2562505734 creator A5008965551 @default.
• W2562505734 creator A5042403689 @default.
• W2562505734 creator A5054457933 @default.
• W2562505734 creator A5068271757 @default.
• W2562505734 creator A5076100718 @default.
• W2562505734 creator A5082133844 @default.
• W2562505734 creator A5091831303 @default.
• W2562505734 date "2015-08-01" @default.
• W2562505734 modified "2023-09-27" @default.
• W2562505734 title "Abstract 5494: Cost analysis of genomic-directed therapy in patients with metastatic lung and colorectal cancers" @default.
• W2562505734 doi "https://doi.org/10.1158/1538-7445.am2015-5494" @default.
• W2562505734 hasPublicationYear "2015" @default.
• W2562505734 type Work @default.
• W2562505734 sameAs 2562505734 @default.
• W2562505734 citedByCount "0" @default.
• W2562505734 crossrefType "proceedings-article" @default.
• W2562505734 hasAuthorship W2562505734A5008965551 @default.
• W2562505734 hasAuthorship W2562505734A5042403689 @default.
• W2562505734 hasAuthorship W2562505734A5054457933 @default.
• W2562505734 hasAuthorship W2562505734A5068271757 @default.
• W2562505734 hasAuthorship W2562505734A5076100718 @default.
• W2562505734 hasAuthorship W2562505734A5082133844 @default.
• W2562505734 hasAuthorship W2562505734A5091831303 @default.
• W2562505734 hasConcept C121608353 @default.
• W2562505734 hasConcept C126322002 @default.
• W2562505734 hasConcept C142724271 @default.
• W2562505734 hasConcept C143998085 @default.
• W2562505734 hasConcept C163763905 @default.
• W2562505734 hasConcept C2776256026 @default.
• W2562505734 hasConcept C526805850 @default.
• W2562505734 hasConcept C60644358 @default.
• W2562505734 hasConcept C71924100 @default.
• W2562505734 hasConcept C86803240 @default.
• W2562505734 hasConceptScore W2562505734C121608353 @default.
• W2562505734 hasConceptScore W2562505734C126322002 @default.
• W2562505734 hasConceptScore W2562505734C142724271 @default.
• W2562505734 hasConceptScore W2562505734C143998085 @default.
• W2562505734 hasConceptScore W2562505734C163763905 @default.
• W2562505734 hasConceptScore W2562505734C2776256026 @default.
• W2562505734 hasConceptScore W2562505734C526805850 @default.
• W2562505734 hasConceptScore W2562505734C60644358 @default.
• W2562505734 hasConceptScore W2562505734C71924100 @default.
• W2562505734 hasConceptScore W2562505734C86803240 @default.
• W2562505734 hasLocation W25625057341 @default.
• W2562505734 hasOpenAccess W2562505734 @default.
• W2562505734 hasPrimaryLocation W25625057341 @default.
• W2562505734 hasRelatedWork W1987679507 @default.
• W2562505734 hasRelatedWork W1999885129 @default.
• W2562505734 hasRelatedWork W2014943657 @default.
• W2562505734 hasRelatedWork W2081608592 @default.
• W2562505734 hasRelatedWork W2145169597 @default.
• W2562505734 hasRelatedWork W2150375803 @default.
• W2562505734 hasRelatedWork W2156619573 @default.
• W2562505734 hasRelatedWork W2306999703 @default.
• W2562505734 hasRelatedWork W2522935852 @default.
• W2562505734 hasRelatedWork W2602610799 @default.
• W2562505734 hasRelatedWork W2605690884 @default.
• W2562505734 hasRelatedWork W2807298143 @default.
• W2562505734 hasRelatedWork W2891924104 @default.
• W2562505734 hasRelatedWork W2979581056 @default.
• W2562505734 hasRelatedWork W2991592191 @default.
• W2562505734 hasRelatedWork W3000646714 @default.
• W2562505734 hasRelatedWork W3095848510 @default.
• W2562505734 hasRelatedWork W3105779279 @default.
• W2562505734 hasRelatedWork W3116081423 @default.
• W2562505734 hasRelatedWork W3131135528 @default.
• W2562505734 isParatext "false" @default.
• W2562505734 isRetracted "false" @default.
• W2562505734 magId "2562505734" @default.
• W2562505734 workType "article" @default.